Dataset from A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009185
下载链接
链接失效反馈官方服务：
资源简介：
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult
subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and
200 mg once daily with a control arm of open-label etravirine (ETV) 200 mg twice daily. The
background ART for all three arms will be darunavir/ritonavir (DRV/r) 600 mg/100 mg twice
daily plus raltegravir (RAL) 400 mg twice daily. Antiviral activity, safety, PK, and
development of viral resistance will be evaluated.
创建时间：
2024-11-27
